By Jeffrey Gelblum, MD As a practicing neurologist with over 25 years of experience treating Alzheimer’s disease, I strongly oppose the proposed intention of Centers for Medicare & Medicaid Services
Medicare to Restrict Coverage of Anti-Amyloid Antibody Therapy for Alzheimer’s Patients Read More »
In recent years, research has shown that tests of cerebrospinal fluid (CSF) can be a valuable tool for the detection of hallmark proteins that are involved in diseases that cause
Leading Florida Neurologists Available to Speak about Biogen Aducanumab Treatment Alzheimer’s patients and their families, as well as the medical community, are celebrating today’s decision by the FDA. They approved
Biogen is planning to file for U.S. regulatory approval for its Alzheimer’s treatment aducanumab after data from more patients in two discontinued studies showed that the drug improved cognition at
Biogen Seeks FDA Approval for New Alzheimer’s Drug Read More »
